Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
A video roundup of the week’s top industry news stories.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
Contract Pharma Stream offers a centralized destination where users can watch expert-led sessions anytime, anywhere
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
44a Grünberger Straße, Berlin, BE, 10243, DE
Mr. Lagarde joins the company from Thermo Fisher Scientific, where he had responsibility for the majority of the company's businesses.
By: Kristin Brooks
Successfully tech-transferred and manufactured first commercial-scale GMP batches of Renaissance Pharma’s lead candidate, Daretabart.
This marks the latest indication in oncology for Imfinzi nine years after the drug’s first approval.
By: Patrick Lavery
Besremi is a treatment for polycythemia vera for which PharmaEssentia is seeking a label expansion to include essential thrombocythemia.
Approval gives adults with BPDCN a new treatment option for this rare, aggressive blood cancer.
By: Charlie Sternberg
The facility becomes the 18th in WuXi Biologics’ global network.
It is the first and only treatment for adults with chronic HDV in the United States.
The manufacturing expansion strengthens domestic supply of Actinium-225.
The succession will be complete by end of summer 2026, but Griffith will remain with the company until January.
Combines direct RNA sequencing, machine learning, and automated analysis to simplify GMP.
Baxfendy is a first-in-class, highly selective, potent aldosterone synthase inhibitor.
The FDA had granted Priority Review for one of the indications in March.
ProtaGene’s expertise in advanced protein characterization and early-stage drug product characterization is complemented by MilliporeSigma’s GMP testing capabilities and global regulatory experience.
Accord BioPharma will be responsible for commercializing IMMGOLIS and IMMGOLIS INTRI in the U.S.
Vesta Bladder Risk Stratify Dx becomes the first AI-powered digital pathology prognostic test in bladder cancer to receive the designation.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
